HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sgouros, G. Articles by Zelenetz, A. D. Search for Related Content PubMed PubMed Citation Articles by Sgouros, G. Articles by Zelenetz, A. D.

Patient-Specific, 3-Dimensional Dosimetry in Non-Hodgkin’s Lymphoma Patients Treated with ¹³¹I-anti-B1 Antibody: Assessment of Tumor Dose-Response

Memorial Sloan-Kettering Cancer Center, New York, New York

A comprehensive, SPECT-based, patient-specific 3-dimensional (3D) dosimetry analysis has been performed using 3D-ID, a previously developed software package. The role of the total-body tumor burden, individual lesion size, tumor absorbed dose, and the spatial distribution of the absorbed dose on response and on the time course of tumor shrinkage has been examined in patients with lymphoma treated by radioimmunotherapy. Methods: Data from 15 patients participating in a phase II study of ¹³¹I-labeled anti-B1 antibody (tositumomab) were used. Patients were administered a tracer dose of ¹³¹I for imaging and pharmacokinetics. Dose estimates from the tracer studies were used to prescribe the therapeutic administration such that the whole-body absorbed dose did not exceed 75 cGy. All patients received a fixed mass amount of antibody for both the tracer and the therapeutic administrations. SPECT and planar imaging were performed 3–4 d after the therapeutic administration. CT or MRI scans were available on all patients. Total tumor burden was assessed by drawing contours around all lymphoma lesions identified on whole-body CT or MRI. Mean absorbed doses were estimated for selected, index lesions by conventional dosimetry and also by 3D SPECT-based dosimetry. Using a patient-specific dosimetry package, 3D-ID, dose-volume histograms were also generated to assess the spatial distribution of absorbed dose. This approach made it possible to obtain estimates of the minimum and maximum absorbed doses for individual tumors in addition to the mean. Results: Mean absorbed dose estimates obtained by patient-specific SPECT-based dosimetry using 3D-ID were within 2%–5% of estimates obtained by conventional dosimetry. None of the absorbed dose parameters (mean, minimum, maximum, uniformity) were found to have a significant correlation with tumor response. The total-body tumor burden did not impact on overall response or toxicity. Conclusion: This analysis represents the first full reported implementation of a patient-specific 3D dosimetry package. The absence of a dose-response relationship for tumors is surprising and suggests that absorbed dose is not the sole determinant of tumor response in these patients. The absence of a correlation between the total-body tumor burden and overall response or toxicity suggests that tailoring the milligram amount of administered antibody to patient tumor burden is not likely to improve response or reduce toxicity.

Key Words: radioimmunotherapy • patient-specific dosimetry • 3D-ID software • tumor dose-response

This article has been cited by other articles:

				A. B. Delaloye, C. Antonescu, T. Louton, J. Kuhlmann, and A. Hagenbeek Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial J. Nucl. Med., November 1, 2009; 50(11): 1837 - 1843. [Abstract] [Full Text] [PDF]

				A. R. Prideaux, H. Song, R. F. Hobbs, B. He, E. C. Frey, P. W. Ladenson, R. L. Wahl, and G. Sgouros Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry J. Nucl. Med., June 1, 2007; 48(6): 1008 - 1016. [Abstract] [Full Text] [PDF]

				K. S. Kolbert, K. S. Pentlow, J. R. Pearson, A. Sheikh, R. D. Finn, J. L. Humm, and S. M. Larson Prediction of Absorbed Dose to Normal Organs in Thyroid Cancer Patients Treated with 131I by Use of 124I PET and 3-Dimensional Internal Dosimetry Software J. Nucl. Med., January 1, 2007; 48(1): 143 - 149. [Abstract] [Full Text] [PDF]

				H. K. Tan, R. W. Wassenaar, and W. Zeng Collimator Selection, Acquisition Speed, and Visual Assessment of 131I-Tositumomab Biodistribution in a Phantom Model J. Nucl. Med. Technol., December 1, 2006; 34(4): 224 - 227. [Abstract] [Full Text] [PDF]

				H. Song, B. He, A. Prideaux, Y. Du, E. Frey, W. Kasecamp, P. W. Ladenson, R. L. Wahl, and G. Sgouros Lung Dosimetry for Radioiodine Treatment Planning in the Case of Diffuse Lung Metastases J. Nucl. Med., December 1, 2006; 47(12): 1985 - 1994. [Abstract] [Full Text] [PDF]

				Y. K. Dewaraja, S. J. Wilderman, M. Ljungberg, K. F. Koral, K. Zasadny, and M. S. Kaminiski Accurate Dosimetry in 131I Radionuclide Therapy Using Patient-Specific, 3-Dimensional Methods for SPECT Reconstruction and Absorbed Dose Calculation J. Nucl. Med., May 1, 2005; 46(5): 840 - 849. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg and R. M. Sharkey Radioimmunotherapy of Non-Hodgkin's Lymphoma Revisited J. Nucl. Med., February 1, 2005; 46(2): 383 - 384. [Full Text] [PDF]

				G. Sgouros Dosimetry of Internal Emitters J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]

				R. L. Wahl Tositumomab and 131I Therapy in Non-Hodgkin's Lymphoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 128S - 140S. [Abstract] [Full Text] [PDF]

				E. J. Postema and K. E. Britton Dosimetry and Radioimmunotherapy of Non-Hodgkin's Lymphoma J. Nucl. Med., December 1, 2004; 45(12): 2126 - 2127. [Full Text] [PDF]

				G. Sgouros, K. S. Kolbert, A. Sheikh, K. S. Pentlow, E. F. Mun, A. Barth, R. J. Robbins, and S. M. Larson Patient-Specific Dosimetry for 131I Thyroid Cancer Therapy Using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) Software J. Nucl. Med., August 1, 2004; 45(8): 1366 - 1372. [Abstract] [Full Text] [PDF]

				D. A. Rizzieri, G. Akabani, M. R. Zalutsky, R. E. Coleman, S. D. Metzler, J. E. Bowsher, B. Toaso, E. Anderson, A. Lagoo, S. Clayton, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma Blood, August 1, 2004; 104(3): 642 - 648. [Abstract] [Full Text] [PDF]

				Y. Du, J. Honeychurch, M. S. Cragg, M. Bayne, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy Blood, February 15, 2004; 103(4): 1485 - 1494. [Abstract] [Full Text] [PDF]

				R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder, A. Alavi, A. Matthies, D. E. Tsai, S. J. Schuster, E. A. Stadtmauer, et al. Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-DOTA Humanized Anti-CD22 IgG (90Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response? J. Nucl. Med., December 1, 2003; 44(12): 2000 - 2018. [Abstract] [Full Text] [PDF]

				K. F. Koral, M. S. Kaminski, R. L. Wahl, G. Sgouros, S. Squeri, A. M. Ballanrud, K. Kolbert, J. B. Teitcher, K. S. Panageas, R. D. Finn, et al. Correlation of Tumor Radiation-Absorbed Dose with Response Is Easier to Find in Previously Untreated Patients J. Nucl. Med., September 1, 2003; 44(9): 1541 - 1543. [Full Text]